Suppr超能文献

大鼠模型中人类脐带间充质干细胞衍生细胞外囊泡动脉内和静脉内递送的生物分布,以指导糖尿病治疗的递送策略

Biodistribution of Intra-Arterial and Intravenous Delivery of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles in a Rat Model to Guide Delivery Strategies for Diabetes Therapies.

作者信息

Li Junfeng, Komatsu Hirotake, Poku Erasmus K, Olafsen Tove, Huang Kelly X, Huang Lina A, Chea Junie, Bowles Nicole, Chang Betty, Rawson Jeffrey, Peng Jiangling, Wu Anna M, Shively John E, Kandeel Fouad R

机构信息

Department of Translational Research & Cellular Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

Department of Radiopharmacy, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

出版信息

Pharmaceuticals (Basel). 2022 May 12;15(5):595. doi: 10.3390/ph15050595.

Abstract

Umbilical cord mesenchymal stem cell-derived extracellular vesicles (UC-MSC-EVs) have become an emerging strategy for treating various autoimmune and metabolic disorders, particularly diabetes. Delivery of UC-MSC-EVs is essential to ensure optimal efficacy of UC-MSC-EVs. To develop safe and superior EVs-based delivery strategies, we explored nuclear techniques including positron emission tomography (PET) to evaluate the delivery of UC-MSC-EVs in vivo. In this study, human UC-MSC-EVs were first successfully tagged with I-124 to permit PET determination. Intravenous (I.V.) and intra-arterial (I.A.) administration routes of [I]I-UC-MSC-EVs were compared and evaluated by in vivo PET-CT imaging and ex vivo biodistribution in a non-diabetic Lewis (LEW) rat model. For I.A. administration, [I]I-UC-MSC-EVs were directly infused into the pancreatic parenchyma via the celiac artery. PET imaging revealed that the predominant uptake occurred in the liver for both injection routes, and further imaging characterized clearance patterns of [I]I-UC-MSC-EVs. For biodistribution, the uptake (%ID/gram) in the spleen was significantly higher for I.V. administration compared to I.A. administration (1.95 ± 0.03 and 0.43 ± 0.07, respectively). Importantly, the pancreas displayed similar uptake levels between the two modalities (0.20 ± 0.06 for I.V. and 0.24 ± 0.03 for I.A.). Therefore, our initial data revealed that both routes had similar delivery efficiency for [I]I-UC-MSC-EVs except in the spleen and liver, considering that higher spleen uptake could enhance immunomodulatory application of UC-MSC-EVs. These findings could guide the development of safe and efficacious delivery strategies for UC-MSC-EVs in diabetes therapies, in which a minimally invasive I.V. approach would serve as a better delivery strategy. Further confirmation studies are ongoing.

摘要

脐带间充质干细胞衍生的细胞外囊泡(UC-MSC-EVs)已成为治疗各种自身免疫性和代谢性疾病,尤其是糖尿病的一种新兴策略。UC-MSC-EVs的递送对于确保其最佳疗效至关重要。为了开发基于细胞外囊泡的安全且卓越的递送策略,我们探索了包括正电子发射断层扫描(PET)在内的核技术,以评估UC-MSC-EVs在体内的递送情况。在本研究中,首先成功地用I-124标记了人UC-MSC-EVs,以进行PET测定。通过体内PET-CT成像和非糖尿病Lewis(LEW)大鼠模型中的体外生物分布,比较并评估了[I]I-UC-MSC-EVs的静脉内(I.V.)和动脉内(I.A.)给药途径。对于I.A.给药,[I]I-UC-MSC-EVs通过腹腔动脉直接注入胰腺实质。PET成像显示,两种注射途径的主要摄取部位均为肝脏,进一步的成像表征了[I]I-UC-MSC-EVs的清除模式。就生物分布而言,I.V.给药时脾脏的摄取量(%ID/克)显著高于I.A.给药(分别为1.95±0.03和0.43±0.07)。重要的是,两种给药方式下胰腺的摄取水平相似(I.V.给药为0.20±0.06,I.A.给药为0.24±0.03)。因此,我们的初步数据显示,除了在脾脏和肝脏中,两种途径对[I]I-UC-MSC-EVs的递送效率相似,考虑到较高的脾脏摄取可能会增强UC-MSC-EVs的免疫调节应用。这些发现可为糖尿病治疗中UC-MSC-EVs安全有效的递送策略的开发提供指导,其中微创I.V.方法将是更好的递送策略。进一步的验证研究正在进行中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f68/9143655/67888e9525f8/pharmaceuticals-15-00595-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验